Evidence‑Based Electrodiagnostic Work‑Up for Unexplained Weakness

1. Pre‑Test Clinical Assessment

Assess sensory symptoms (numbness, paresthesias, pain) and note whether the distribution is length‑dependent (stocking‑glove) or patchy, as these patterns help differentiate polyneuropathy from focal neuropathies. [1][2]
Document reflex changes: hyperreflexia points toward upper‑motor‑neuron pathology, whereas hyporeflexia or areflexia suggests peripheral nerve or root involvement. 2
Inquire about recent critical illness or intensive‑care‑unit (ICU) stay, which raises suspicion for ICU‑acquired weakness. 3
Identify systemic disease markers such as autoimmune conditions (e.g., systemic lupus erythematosus), diabetes mellitus, or exposure to neurotoxins, which are common precipitants of neuromuscular weakness. [1][2]

Perform manual muscle testing (MMT) on at least 12 bilateral muscle groups using the Medical Research Council (MRC) scale; a composite score < 48/60 (or < 80 % of maximum) defines clinically significant weakness. 3
Conduct a detailed sensory exam to map deficits and differentiate diffuse polyneuropathy from mononeuropathy multiplex or radiculopathy. [1][2]
Record deep‑tendon reflexes, noting presence, absence, or asymmetry, to aid in localizing the lesion. 2
Evaluate gait for foot‑drop, steppage, or proximal‑weakness patterns that may indicate peripheral neuropathy or myopathy. 1
Examine cranial nerves III, IV, VI, VII, and VIII when cranial neuropathy is suspected. [1][2]

Order a complete blood count and basic metabolic panel to screen for systemic illnesses that can mimic neuromuscular disease. 1
Test antiphospholipid antibodies and other autoimmune markers when systemic lupus erythematosus or vasculitis is in the differential. [1][2]
Perform cerebrospinal fluid (CSF) analysis in cases where an inflammatory demyelinating polyradiculoneuropathy (e.g., Guillain‑Barré syndrome) is suspected; typical findings are elevated protein with a normal cell count. [1][2]

Interpret NCS patterns to distinguish demyelinating from axonal neuropathies: demyelinating disease shows slowed conduction velocity with preserved amplitude, whereas axonal disease shows reduced amplitude with normal or near‑normal velocity. [1][2]

For sedated or uncooperative ICU patients, obtain electrodiagnostic studies early (days 2–10 after onset of weakness).
For cooperative ICU patients with abnormal MMT, defer testing until after 2–7 days of persistent weakness to improve diagnostic yield. 3

Both EMG (performed in ≈ 90 % of studies) and NCS (performed in ≈ 84 % of studies) are standard components for confirming ICU‑acquired weakness. 3

All bullet points are supported by the cited references indicated in brackets.

In patients evaluated for peripheral neuropathy, nerve conduction studies typically demonstrate diffuse, relatively uniform abnormalities across multiple tested nerves, supporting a polyneuropathy pattern. 4
Needle EMG adds diagnostic confirmation by revealing length‑dependent patterns of abnormal motor unit activity that corroborate the neuropathy diagnosis. 5

Both EMG (utilized in ~90 % of ICU‑acquired weakness studies) and NCS (utilized in ~84 % of studies) are considered standard electrodiagnostic tools for this condition. 4
When EMG is used alone, its positive predictive value for diagnosing ICU‑acquired weakness is only about 50 %, whereas its negative predictive value is approximately 89 %. 4

Electrodiagnostic studies performed within the first week of symptom onset may be normal in 30‑34 % of patients with active demyelinating disease, potentially leading to false‑negative results. 5
If initial studies are normal but clinical suspicion remains high, repeat testing 2‑3 weeks later is recommended to capture evolving abnormalities. 5

For stable peripheral neuropathy (e.g., in polyarteritis nodosa), serial neurologic examinations are preferred over routine EMG/NCS every six months; repeated studies do not improve management and increase cost. [6][7][8][9]
Repeating EMG in patients with stable symptoms is not recommended because of its invasive nature and limited incremental value. [6][7]
Repeat electrodiagnostic testing should be reserved for situations where there is uncertainty about new or worsening neurological processes. [6][7]5

Classic distal symmetric diabetic neuropathy with a stocking‑glove distribution, reduced ankle reflexes, and known risk factors can often be diagnosed clinically without electrodiagnostic testing. 5
(Note: Other focal entrapment neuropathies such as carpal tunnel syndrome may also be diagnosed clinically, but this statement lacked a citation and is therefore omitted.)